Mariner’s VanEck Pharmaceutical ETF PPH Stock Holding History

Mariner’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-24,398	Closed	-$1.9M	–	2860
2022 Q4	$1.9M	Buy	+24,398	New	+$1.8M	0.01%	953

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

VAS

Valicenti Advisory Services Elmira, New York $530M AUM 46.5% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Mariner's PPH Position: Q1 2023 in Review

Mariner sold out of VanEck Pharmaceutical ETF (PPH) in Q1 2023, closing a stake of 24,398 shares — an estimated $1.9M sold.

Mariner first reported a position in PPH in Q4 2022 and held it in 1 quarter. The position peaked at $1.9M in Q4 2022. 106 funds tracked by Wall St. Rank hold PPH as of Q1 2023.

Mariner reported no remaining VanEck Pharmaceutical ETF position as of Q1 2023 after selling out during the quarter.
Mariner sold 24,398 VanEck Pharmaceutical ETF shares in Q1 2023, an estimated $1.9M.
Mariner first reported a position in VanEck Pharmaceutical ETF in Q4 2022 and held it in 1 quarter.
Mariner's VanEck Pharmaceutical ETF position peaked at $1.9M in Q4 2022.
106 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2023.

Based on Mariner's 13F filing for Q1 2023, filed 15 May 2023.